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the validated, Canadian risk scoring model were sensitive to
the resulting variation in RSV-related hospitalization rates. In
instances where risk was low, palivizumab was not cost-effective.
However, for infants with at least moderate risk (2 or more risk
factors), palivizumab had incremental costs per QALY that indi-
cated moderate to strong evidence for adoption (range: $1,598 to
$30,819 per QALY). CONCLUSION: Palivizumab was cost-
effective and our model supports prophylaxis for infants born at
32 to 35 weeks GA, particularly those with moderate risk of
RSV.
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To make appropriate use of the growing economic evidence
base in health care, developing countries need applications rel-
evant to their own national health objectives. One objective is
protection for individuals and governments against the ﬁnancial
risks of ill health, more critical in low-resource settings. Yet,
advancements in cost-effectiveness analysis (CEA) have not
focused on the importance of efﬁciency in contributing to this
goal. The lowest income nations also rely heavily on external
funds from donor countries and organizations. While the recent
emergence of non-traditional donors has greatly increased
funding levels for global health, the large scale, narrow focus
and time limitations of some of the funding have also raised
questions of their effects on national health priorities as well as
on the opportunity costs of the interventions supported by this
funding. In attaining efﬁciency with a view towards minimizing
ﬁnancial risk, CEA must address two issues in this case: that the
additional resources are efﬁciently allocated and that the
resources themselves are not a source of ﬁnancial risk. This
doctoral project proposes a conceptual framework for a CEA
“reference case” in the broader context of health ﬁnancing in
developing countries. Suggested modiﬁcations of the prevailing
reference cases are literature-based, iteratively guided by key
informants. Costing and sensitivity analysis with respect to
external funding are highlighted. An application to the intro-
duction of rotavirus immunization illustrates the framework.
The conceptual framework anticipates the imminent introduc-
tion of expensive new vaccines targeted at resource-poor, donor-
dependant health systems. It allows analysts and policy-makers
to harmonize efﬁciency and ﬁnancial risk objectives. It also
helps donors in assessing aid effectiveness of assisted programs.
Ultimately, this framework improves the transferability and gen-
eralizability of existing CEA results by suggesting adjustments
relevant to developing countries.
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OBJECTIVE: Treatment of preterm labour constitutes consider-
able inpatient cost, and use of tocolytics is central in delaying
birth to allow neonatal lungs to mature. The study aimed to
compare cost implications of adverse events following tocolysis
with atosiban and beta-mimetics. METHODS: Major literature
databases were systematically searched to identify randomised
clinical trials comparing atosiban with beta-mimetics during the
initial 48 h of hospitalisation. Adverse events data from three
double blind trials were included in a meta-analysis. Clinical
resource use was determined based on routine practice in a
regional German hospital. Cost of drug treatment was calculated
based on trial protocols and German hospital drug purchase
costs; analysis was performed for fenoterol, the only beta-
mimetic licensed in Germany for tocolysis. Costs per case were
calculated with G-DRG Grouper. Costs were expressed in €2007.
RESULTS: Use of atosiban was associated with signiﬁcantly
lower frequency of adverse events compared to beta-mimetics.
From the payer’s perspective, cost-saving from using atosiban
versus fenoterol was €423 per patient starting treatment. From
the hospital’s perspective, savings from using atosiban versus
continuous fenoterol ranged from €259 for 18 hours of tocolysis
to €105 for 48 hours; the respective values for bolus fenoterol
were €244 and €55. From the combined perspective, using
atosiban versus continuous fenoterol saved from €226 for 18
hours of tocolysis to €71 for 48 hours; versus bolus fenoterol the
results were €211 and €21, respectively. In the probabilistic sen-
sitivity analysis atosiban was cost-saving versus both continuous
and bolus fenoterol in 100% of iterations at 18 hours and in at
least 87% of iterations at 48 hours. CONCLUSION: Atosiban
was cost-saving versus beta-mimetics in the treatment of preterm
labour in Germany from the payer’s, hospital’s and combined
perspectives. The results were robust in the probabilistic sensi-
tivity analysis.
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OBJECTIVE: Given the complexity of the Medicare Part D
(MPD) prescription drug beneﬁt, many Medicare beneﬁciaries
lack the knowledge and experience to select optimal MPD pre-
scription drug plans. This challenge is exacerbated in low-income
and other vulnerable populations. A Cost-Minimization Analysis
(CMA) was performed to determine whether and to what extent
student pharmacists’ interventions reduce out-of-pocket
(OOP) prescription drug plan costs for Medicare beneﬁciaries.
METHODS: Trained student pharmacists throughout California
provided one-on-one MPD prescription drug plan consultations
during community outreach events. Cost information for the
participant’s current and lowest-cost plan for 2008 was obtained
by conducting a personalized plan search using the online MPD
Plan Finder tool. RESULTS: Twenty-two outreach events were
conducted statewide and data were collected from 250 Medicare
beneﬁciaries. The mean  SD age of the participants was
74.3  9.1 years, and 91 (36.4%) were male. The mean  SD
(range) number of prescription drugs per participant was
5.6  3.9 (0–26). Eighty-three participants (33.2%) had limited
or no English proﬁciency, 82 (32.8%) had less than a high school
education, and 102 (40.8%) were enrolled in both Medicare and
Medicaid. Data from 95 participants (72 of whom were not
enrolled in a MPD drug plan during 2007 and 23 of whom had
incomplete data) were necessarily excluded for purposes of the
CMA. For the other 155 participants, the median annual OOP
costs for continued enrollment in their current MPD prescription
drug plan in 2008 were $440.00, compared to $200.00 for the
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lowest-cost 2008 plan. When cost savings were calculated by
individual participant, this equated to a median annual OOP cost
savings of $98.00 (22.3%) per participant. CONCLUSION:
Trained student pharmacists can provide community-based inter-
ventions that reduce OOP prescription drug plan costs among
underserved Medicare populations.
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OBJECTIVE: Falls in the elderly pose signiﬁcant health risk with
substantial effects on health resource utilization and cost; 95% of
hip fractures are due to falls. Previous estimates of the costs of
falls used administrative data which underestimate falls inci-
dence. We aimed to estimate the direct health costs of injurious
falls requiring Emergency Department (ED) care. METHODS:
Information was collected on patients >70 years who presented
to the ED of Vancouver General Hospital. Fallers were identiﬁed
though a search of ED census, ED presenting complaints, ED
consultant records, and patient charts for reports of a fall. From
hospital reports, data were collected on patient demographics,
diagnoses, admission status, and hospital length of stay. Total
costs were estimated for each fall from the third payer perspec-
tive. Unit cost estimates for ED visits, and hospitalizations were
taken from a fully allocated hospital cost model. RESULTS:
Between December 1 2006 and March 31 2007, we identiﬁed
390 falls by 381 individuals costing $2,520,641. The mean age of
fallers was 83.6 years (SD:7.4); 69% were women. Fallers sus-
tained 183 (47%) fractures—these included 70 hip (39%) and
22 pelvic (12%) fractures. Other common diagnoses were
contusions/lacerations (n = 63, 16%), and syncope (n = 31, 8%).
134 (34%) falls resulted in hospital admission with an average
length of stay of 31.6 days (SD:41.59) and mean cost of $18,375
(SD:23601). Logistic regression analysis showed that compared
to those <80 years, those >80 years were more likely to be
hospitalized (OR:1.8, 95% CI:1.1–3.0). Women were more likely
than men to be hospitalized (OR = 1.5, 95% CI:0.9–2.4),
however this association was not statistically signiﬁcant. After
adjusting for age and sex, a diagnosis of “fracture” was the
strongest predictor of hospitalization (OR:15.5, 95% CI:8.2–
27.2). CONCLUSION: Among seniors, the signiﬁcant cost of fall
related hospital admissions warrants increased fall prevention
programs in this population.
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OBJECTIVE: Uterine ﬁbroids are the most common tumours in
women during their reproductive years, yet there is consider-
able paucity of data on treatments’ effectiveness and costs. We
developed a Markov model to compare currently available
treatments with a new Magnetic Resonance Guided Focused
Ultrasound Sound Surgery (MRgFUS). METHODS: Current
practice, comprising of uterine artery embolization (UAE),
myomectomy and hysterectomy, was compared with MRgFUS,
the least invasive procedure. A Markov model was used to
simulate the clinical outcomes, costs, age and quality-of-life
parameters to provide informed decisions on the part of pro-
viders, payers, and patients. The results were expressed as costs
per quality- adjusted-life-year (QALY) gained. The analysis was
conducted from the perspective of the National Health Service
(NHS) in the UK. All model parameters were based on the
most recent literature (post 1999). The effects of uncertainty in
the model’s parameters were explored using extensive determin-
istic and probabilistic sensitivity analysis. RESULTS: MRgFUS
is likely to be cost-effective. In the base scenario, it is dominant,
that is, has a lower cost and better outcomes than existing
treatments, although the QALY difference per woman is small.
MRgFUS remains cost effective (30, 000 per QALY gained)
when using alternative assumptions regarding current practice,
health utility, and the effectiveness of alternative treatments
(complication, recurrence, and procedural death rates). Mul-
tiple simulations show the range of outcomes that might be
expected in all aspects of practice with the result that MRgFUS
remains cost-effective in more than 86% of the simulations.
CONCLUSION: The results of this study support the introduc-
tion of MRgFUS as a treatment for uterine ﬁbroids. A treat-
ment strategy starting with MRgFUS is potentially more
effective and less costly than the current practice.
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OBJECTIVE: A woman’s health-related quality of life (HRQoL)
can be affected by her premenstrual symptoms. The study objec-
tive was to assess the association between HRQoL and score
differences on the Premenstrual Symptoms Impact Survey
(PMSIS), a six-item instrument for measuring impact of premen-
strual symptoms on a woman’s HRQoL. METHODS: Data were
collected on the PMSIS and SF-12 Health Survey from a panel of
representative U.S. women 18–45 years via Internet (N = 971).
PMSIS scores were used to identify women “at risk for PMDD.”
Items from the SF-12 were dichotomized and regressed onto the
standardized PMSIS scores with age as a covariate. Logistic
regression was used to derive odds ratios (OR) for experiencing
a particular outcome as a function of score differences between
“at risk for PMDD” and the population mean of the PMSIS.
RESULTS: The overall sample mean PMSIS score was 26.6 (on a
standardized scale of 0–100 from no impact to severe impact).
Higher PMSIS scores were signiﬁcantly associated with increased
risk of negative HRQL outcomes (p < 0.01). Women identiﬁed as
“at risk for PMDD” (PMSIS score  64) had 383% increased
risk of pain interfering with normal work; 320% increased risk
of doing work or activities less carefully than usual due to emo-
tional problems; 253% increased risk of feeling limited in work
or activities due to physical health or feeling they accomplished
less due to emotional problems; and 196% increased risk of
feeling downhearted and depressed, and feeling little or no
energy. CONCLUSION: There is a signiﬁcant association
between higher PMSIS scores (more severe impact due to pre-
menstrual symptoms) and diminished role functioning, physical
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